NCT01851824View on ClinicalTrials.gov

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Malignant Melanoma, Neoplasms

Interventions

DRUG

acenocoumarol

4 mg single oral doses on Days 1 and 23

DRUG

vemurafenib

960 mg orally bid, 20 days (Days 4-23)

Trial Locations (20)

1122

Budapest

1142

Auckland

3690

Wodonga

8011

Christchurch

11000

Belgrade

21614

Buxtehude

28031

Madrid

28040

Madrid

28050

Madrid

45122

Essen

56429

Thessaloniki

68167

Mannheim

71110

Crete

1066 CX

Amsterdam

6229HX

Maastricht

3584 CX

Utrecht

1099-023

Lisbon

4200-072

Porto

08036

Barcelona

08908

Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01851824 - A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | Biotech Hunter | Biotech Hunter